Press Lantern

News, held to the light

Science

FDA Orders Blindness-Risk Warning on GLP-1 Weight-Loss Drugs

Labels for semaglutide and tirzepatide must flag a rare but serious eye condition, a significant regulatory step for the blockbuster class.

FDA Orders Blindness-Risk Warning on GLP-1 Weight-Loss Drugs
Labels for semaglutide and tirzepatide must flag a rare but serious eye condition, a significant regulatory step for the blockbuster class. AI-generated illustration for Press Lantern

The FDA ordered manufacturers of GLP-1 weight-loss and diabetes drugs, including semaglutide and tirzepatide, to add warnings about a rare eye condition that can cause sudden vision loss.

The requirement follows reports and studies linking the drugs to non-arteritic anterior ischemic optic neuropathy, a stroke of the optic nerve. Regulators stressed the condition is rare relative to the tens of millions of users.

The drugs rank among the best-selling pharmaceuticals in history, reshaping obesity treatment and the fortunes of their makers. Companies said they would comply and noted that overall safety profiles remain favorable.

Physicians said patients should not stop the medications without consultation but should report sudden vision changes immediately. Analysts expect minimal commercial impact, though the ruling may prompt closer monitoring of long-term effects.

FDA Pharmaceuticals Public Health

← Back to the front page